US life sciences damages averaged $33.5m between 2019-2025

Despite a slowdown in US patent litigation, life sciences remains one of the most active sectors—but companies are using a wider than ever IP toolkit, says a new study.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com

More on this story

Regulation & Industry

The buyers' wishlist: What makes a life sciences deal stack up?

25 August 2026 While promising science draws in buyers, intellectual property determines the price, terms, and viability of an agreement. LSIPR digs into what investors are looking for—and the biggest turn-offs that destroy a deal.

Regulation & Industry

UK appoints ex-engineer as new intellectual property Minister

24 August 2026 Labour MP for Stockton North takes up a new role as Minister for Science, Innovation and Investment within Andy Burnham’s government.

Regulation & Industry

Exclusive: ‘In the end, I did it my own way’ and became a UPC judge

12 August 2026 Unified Patent Court judge Margot Kokke has had an unconventional and oft-interrupted career as the “trailing spouse” of a diplomat. She talks to Sarah Speight about this and more in the fourth in a series of interviews with women judges at the court.

More features

Paul, Weiss finds appellate ‘star’ to lead Supreme Court practice

The buyers' wishlist: What makes a life sciences deal stack up?

UK appoints ex-engineer as new intellectual property Minister

Stris & Maher opens new Dallas office with partner hires

Teva and Aurinia settle generics dispute over lupus drug, voclosporin

10x Genomics dealt major blow in sequencing fight

SK Biopharmaceuticals settles epilepsy generic dispute

Vanda revives challenge over braille-free label on generic sleep disorder drug

US life sciences damages averaged $33.5m between 2019-2025

More on this story

Editor's picks

Editor's picks

More features